VistaGen Therapeutics

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system disorders. Its portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder, PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101, which the company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia, and epilepsy. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Earnings data Q3 2026

Earnings data Q4 2026

VistaGen Therapeutics reports Q1 loss, focuses on FDA approval

VistaGen Therapeutics faces financial challenges with increased expenses but shows strength in its innovative drug candidates targeting mental health disorders. The company's opportunities lie in FDA approval for fasedienol and market expansion for its pherine drug candidates.

VistaGen reports positive trial results and financial stability in Q2

VistaGen Therapeutics showcased positive trial results and financial stability, emphasizing the potential of their pherine pipeline to create value and improve lives.
While facing challenges such as increased expenses and operational concerns, the company's commitment to advancing treatments presents opportunities for growth and market expansion.
Analyst interest in study details and timelines reflects investor confidence in VistaGen's research programs and potential market impact.
Overall, VistaGen's Q2 performance highlights progress in lead programs and a solid financial foundation for future growth and innovation.

VistaGen reports Q3 progress in neuroscience programs amid market challenges

VistaGen Therapeutics' Q3 performance reflects strategic investments in R&D and promising progress in lead neuroscience programs. The company faces challenges in study execution and regulatory implications but remains optimistic about market differentiation and growth opportunities. VistaGen's strengths lie in its unique pipeline approach, rigorous study protocols, and diversified product portfolio. Opportunities for VistaGen include market expansion, breakthrough developments, and investor confidence in its strategic direction.

VistaGen Therapeutics advances neuroscience program with promising clinical-stage candidates

VistaGen Therapeutics showcased progress in its neuroscience program, with upcoming data readouts and positive reception for its pherine product candidates. While facing financial challenges, the company aims to capitalize on its innovative pipeline and stakeholder support to drive transformation and growth.

Vistagen Therapeutics reports progress in neuroscience programs and financials

Vistagen Therapeutics showcased financial performance, program advancements, and strategic hires during the Q1 2026 earnings call. Analyst interest in trial progress and upcoming data releases underscores market anticipation and scrutiny. The company's commitment to innovation and growth bodes well for future developments and potential market impact.

Vistagen Therapeutics advances clinical programs with strong financial backing

Vistagen Therapeutics is progressing well in its clinical programs, bolstered by a strong financial position and a focused leadership team. While facing inquiries on various operational aspects, the company's strategic direction and mission offer promising growth opportunities in the neuroscience sector.

VistaGen advances clinical trials and data analysis for growth

VistaGen Therapeutics showcased significant progress in key clinical trials and data analysis, underlining a commitment to innovation and value creation. While facing regulatory and competitive challenges, the company's strong financial position and diversified pipeline position them well for future growth and success. Opportunities lie in leveraging innovative approaches, expanding therapeutic areas, and exploring strategic partnerships to drive continued advancement and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.